ALNYLAM PHARMACEUTICALS (ALNY) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$232.68
+3.6% on the day
-49.1% over 12 months
52-week range $205.48 – $491.22
Share price and insider trades
ALNY closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$44.0M
Insiders buying0
Insiders selling8
ALNYLAM PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $44.0M of ALNY stock on the open market.
Get emailed when insiders cluster-buy stocks like ALNY
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ALNY insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $399K | 1 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | $2.4M | 19 |
| Q1 2026 | — | 0 | $24.0M | 228 |
| Q4 2025 | — | 0 | $4.0M | 2 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.7×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 ALNYLAM PHARMACEUTICALS, INC. insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $44.0M. 107 of 250 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ALNY earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Jul 30, 2026 | +1.9% | None | -28.3%S&P +2.4% | +15.4% |
| Apr 30, 2026 | -11.3% | Sold $1.3M | -1.7%S&P +1.3% | +2.0% |
| Feb 12, 2026 | -9.2% | Sold $848K | -2.4%S&P -1.5% | -0.3% |
| Jan 12, 2026 | -0.6% | None | -7.1%S&P -0.0% | -16.6% |
| Oct 30, 2025 | +2.6% | Sold $10.2M | -5.3%S&P -0.8% | -1.1% |
| Jul 31, 2025 | +9.2% | None | +18.2%S&P -2.0% | +11.1% |
| Jan 13, 2025 | -1.9% | None | +1.1%S&P +0.3% | +10.1% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Members of Congress who traded ALNY
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Cory A BookerSenate | Sold $1,001 - $15,000 | Aug 11, 2026 | Sep 9, 2026 | +5.2% |
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 6SEC | Bryan SupranGeneral Counsel | Sell | 1,75812,807 held (−12%) | $226.88 | $399K | +2.6% | — |
| Jun 3SEC | David E I PyottDirector | Sell Plan | 1,2222,094 held (−37%) | $299.87 | $366K | -22.4% | — |
| Jun 3SEC | David E I PyottDirector | Sell Plan | 1,1753,316 held (−26%) | $298.91 | $351K | -22.2% | — |
| Jun 3SEC | David E I PyottDirector | Sell Plan | 9214,491 held (−17%) | $297.71 | $274K | -21.8% | — |
| Jun 3SEC | David E I PyottDirector | Sell Plan | 4951,599 held (−24%) | $300.72 | $149K | -22.6% | — |
| Jun 3SEC | David E I PyottDirector | Sell Plan | 171,582 held (−1%) | $302.65 | $5K | -23.1% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 90910,764 held (−8%) | $329.76 | $300K | -29.4% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 8299,935 held (−8%) | $330.46 | $274K | -29.6% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 35912,729 held (−3%) | $317.44 | $114K | -26.7% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 2939,642 held (−3%) | $331.89 | $97K | -29.9% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 26513,088 held (−2%) | $316.61 | $84K | -26.5% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 24511,818 held (−2%) | $322.86 | $79K | -27.9% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 22412,063 held (−2%) | $321.64 | $72K | -27.7% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 20912,520 held (−2%) | $318.47 | $67K | -26.9% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 1999,443 held (−2%) | $333.94 | $66K | -30.3% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 14712,287 held (−1%) | $320.62 | $47K | -27.4% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 8612,434 held (−1%) | $319.69 | $27K | -27.2% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 8111,737 held (−1%) | $323.64 | $26K | -28.1% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 5611,673 held (−0%) | $320.14 | $18K | -27.3% | — |
| Apr 7SEC | Melissa MclaughlinChief Human Resources Officer | Sell Plan | 811,729 held (−0%) | $325.49 | $3K | -28.5% | — |
| Mar 6SEC | Yvonne GreenstreetCEO | Sell | 97396,305 held (−1%) | $323.84 | $315K | -28.1% | — |
| Mar 6SEC | Jeffrey V. PoultonCFO | Sell | 81862,319 held (−1%) | $323.84 | $265K | -28.1% | — |
| Mar 6SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 76734,777 held (−2%) | $323.84 | $248K | -28.1% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 76721,577 held (−3%) | $323.84 | $248K | -28.1% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 74019,703 held (−4%) | $323.55 | $239K | -28.1% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 65420,443 held (−3%) | $322.33 | $211K | -27.8% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 51019,193 held (−3%) | $324.59 | $166K | -28.3% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 50018,693 held (−3%) | $326.08 | $163K | -28.6% | — |
| Mar 6SEC | Yvonne GreenstreetCEO | Sell | 44497,278 held (−0%) | $323.01 | $143K | -28.0% | — |
| Mar 6SEC | Jeffrey V. PoultonCFO | Sell | 37463,137 held (−1%) | $323.01 | $121K | -28.0% | — |
| Mar 6SEC | Yvonne GreenstreetCEO | Sell | 36897,722 held (−0%) | $321.82 | $118K | -27.7% | — |
| Mar 6SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 35035,544 held (−1%) | $323.01 | $113K | -28.0% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 35022,344 held (−2%) | $323.01 | $113K | -28.0% | — |
| Mar 6SEC | Yvonne GreenstreetCEO | Sell | 34595,960 held (−0%) | $324.88 | $112K | -28.4% | — |
| Mar 6SEC | Jeffrey V. PoultonCFO | Sell | 30963,511 held (−0%) | $321.82 | $99K | -27.7% | — |
| Mar 6SEC | Jeffrey V. PoultonCFO | Sell | 29162,028 held (−0%) | $324.88 | $95K | -28.4% | — |
| Mar 6SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 28935,894 held (−1%) | $321.82 | $93K | -27.7% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 28922,694 held (−1%) | $321.82 | $93K | -27.7% | — |
| Mar 6SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 27234,505 held (−1%) | $324.88 | $88K | -28.4% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 27221,305 held (−1%) | $324.88 | $88K | -28.4% | — |
| Mar 6SEC | Yvonne GreenstreetCEO | Sell | 27498,090 held (−0%) | $320.81 | $88K | -27.5% | — |
| Mar 6SEC | Yvonne GreenstreetCEO | Sell | 26595,695 held (−0%) | $325.67 | $86K | -28.6% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 23320,870 held (−1%) | $323.25 | $75K | -28.0% | — |
| Mar 6SEC | Jeffrey V. PoultonCFO | Sell | 23063,820 held (−0%) | $320.81 | $74K | -27.5% | — |
| Mar 6SEC | Jeffrey V. PoultonCFO | Sell | 22361,805 held (−0%) | $325.67 | $73K | -28.6% | — |
| Mar 6SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 21536,183 held (−1%) | $320.81 | $69K | -27.5% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 21522,983 held (−1%) | $320.81 | $69K | -27.5% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 21021,359 held (−1%) | $323.84 | $68K | -28.1% | — |
| Mar 6SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 20834,297 held (−1%) | $325.67 | $68K | -28.6% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 20821,097 held (−1%) | $325.67 | $68K | -28.6% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 15320,569 held (−1%) | $326.24 | $50K | -28.7% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 14820,722 held (−1%) | $324.60 | $48K | -28.3% | — |
| Mar 6SEC | Yvonne GreenstreetCEO | Sell | 13598,493 held (−0%) | $319.03 | $43K | -27.1% | — |
| Mar 6SEC | Yvonne GreenstreetCEO | Sell | 12998,364 held (−0%) | $320.01 | $41K | -27.3% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 12421,103 held (−1%) | $321.81 | $40K | -27.7% | — |
| Mar 6SEC | Jeffrey V. PoultonCFO | Sell | 11464,159 held (−0%) | $319.03 | $36K | -27.1% | — |
| Mar 6SEC | Jeffrey V. PoultonCFO | Sell | 10964,050 held (−0%) | $320.01 | $35K | -27.3% | — |
| Mar 6SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 10636,500 held (−0%) | $319.03 | $34K | -27.1% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 10623,300 held (−0%) | $319.03 | $34K | -27.1% | — |
| Mar 6SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 10236,398 held (−0%) | $320.01 | $33K | -27.3% | — |
| Mar 6SEC | Pushkal GargEvp Chief R&D | Sell Plan | 10223,198 held (−0%) | $320.01 | $33K | -27.3% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 9621,569 held (−0%) | $323.01 | $31K | -28.0% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 7921,665 held (−0%) | $321.82 | $25K | -27.7% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 7521,284 held (−0%) | $324.88 | $24K | -28.4% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 5921,744 held (−0%) | $320.81 | $19K | -27.5% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 5721,227 held (−0%) | $325.67 | $19K | -28.6% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 2921,831 held (−0%) | $319.03 | $9K | -27.1% | — |
| Mar 6SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 2821,803 held (−0%) | $320.01 | $9K | -27.3% | — |
| Mar 4SEC | Yvonne GreenstreetCEO | Sell | 1,669102,078 held (−2%) | $326.81 | $545K | -28.8% | — |
| Mar 4SEC | Yvonne GreenstreetCEO | Sell | 1,399100,679 held (−1%) | $327.67 | $458K | -29.0% | — |
| Mar 4SEC | Yvonne GreenstreetCEO | Sell | 1,098103,747 held (−1%) | $325.63 | $358K | -28.5% | — |
| Mar 4SEC | Yvonne GreenstreetCEO | Sell | 72299,533 held (−1%) | $329.71 | $238K | -29.4% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 72222,219 held (−3%) | $320.51 | $231K | -27.4% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 64023,869 held (−3%) | $320.48 | $205K | -27.4% | — |
| Mar 4SEC | Jeffrey V. PoultonCFO | Sell | 54165,393 held (−1%) | $326.81 | $177K | -28.8% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 46323,406 held (−2%) | $321.50 | $149K | -27.6% | — |
| Mar 4SEC | Jeffrey V. PoultonCFO | Sell | 45464,939 held (−1%) | $327.67 | $149K | -29.0% | — |
| Mar 4SEC | Yvonne GreenstreetCEO | Sell | 424100,255 held (−0%) | $328.71 | $139K | -29.2% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 42126,053 held (−2%) | $326.81 | $138K | -28.8% | — |
| Mar 4SEC | Yvonne GreenstreetCEO | Sell | 39998,788 held (−0%) | $331.93 | $132K | -29.9% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 39224,323 held (−2%) | $326.81 | $128K | -28.8% | — |
| Mar 4SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 39237,417 held (−1%) | $326.81 | $128K | -28.8% | — |
| Mar 4SEC | Yvonne GreenstreetCEO | Sell | 382104,845 held (−0%) | $324.65 | $124K | -28.3% | — |
| Mar 4SEC | Jeffrey V. PoultonCFO | Sell | 35665,934 held (−1%) | $325.63 | $116K | -28.5% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 35325,700 held (−1%) | $327.67 | $116K | -29.0% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 35921,860 held (−2%) | $321.58 | $115K | -27.6% | — |
| Mar 4SEC | Yvonne GreenstreetCEO | Sell | 34699,187 held (−0%) | $330.85 | $114K | -29.7% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 35524,826 held (−1%) | $316.74 | $112K | -26.5% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 32923,994 held (−1%) | $327.67 | $108K | -29.0% | — |
| Mar 4SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 32937,088 held (−1%) | $327.67 | $108K | -29.0% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 31724,509 held (−1%) | $319.06 | $101K | -27.1% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 28923,223 held (−1%) | $316.55 | $91K | -26.5% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 27726,474 held (−1%) | $325.63 | $90K | -28.5% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 28222,941 held (−1%) | $318.62 | $90K | -27.0% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 25824,715 held (−1%) | $325.63 | $84K | -28.5% | — |
| Mar 4SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 25837,809 held (−1%) | $325.63 | $84K | -28.5% | — |
| Mar 4SEC | Jeffrey V. PoultonCFO | Sell | 23464,567 held (−0%) | $329.71 | $77K | -29.4% | — |
| Mar 4SEC | Yvonne GreenstreetCEO | Sell | 200105,227 held (−0%) | $323.62 | $65K | -28.1% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 18225,411 held (−1%) | $329.71 | $60K | -29.4% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 17023,724 held (−1%) | $329.71 | $56K | -29.4% | — |
| Mar 4SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 17036,818 held (−0%) | $329.71 | $56K | -29.4% | — |
| Mar 4SEC | Yvonne GreenstreetCEO | Sell | 16098,628 held (−0%) | $332.64 | $53K | -30.1% | — |
| Mar 4SEC | Jeffrey V. PoultonCFO | Sell | 13864,801 held (−0%) | $328.71 | $45K | -29.2% | — |
| Mar 4SEC | Jeffrey V. PoultonCFO | Sell | 12964,326 held (−0%) | $331.93 | $43K | -29.9% | — |
| Mar 4SEC | Jeffrey V. PoultonCFO | Sell | 12466,290 held (−0%) | $324.65 | $40K | -28.3% | — |
| Mar 4SEC | Jeffrey V. PoultonCFO | Sell | 11264,455 held (−0%) | $330.85 | $37K | -29.7% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 10725,593 held (−0%) | $328.71 | $35K | -29.2% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 10125,223 held (−0%) | $331.93 | $34K | -29.9% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 10023,894 held (−0%) | $328.71 | $33K | -29.2% | — |
| Mar 4SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 10036,988 held (−0%) | $328.71 | $33K | -29.2% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 9726,751 held (−0%) | $324.65 | $31K | -28.3% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 9423,549 held (−0%) | $331.93 | $31K | -29.9% | — |
| Mar 4SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 9436,643 held (−0%) | $331.93 | $31K | -29.9% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 9024,973 held (−0%) | $324.65 | $29K | -28.3% | — |
| Mar 4SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 9038,067 held (−0%) | $324.65 | $29K | -28.3% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 8725,324 held (−0%) | $330.85 | $29K | -29.7% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 8123,643 held (−0%) | $330.85 | $27K | -29.7% | — |
| Mar 4SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 8136,737 held (−0%) | $330.85 | $27K | -29.7% | — |
| Mar 4SEC | Jeffrey V. PoultonCFO | Sell | 6566,414 held (−0%) | $323.62 | $21K | -28.1% | — |
| Mar 4SEC | Jeffrey V. PoultonCFO | Sell | 5364,273 held (−0%) | $332.64 | $18K | -30.1% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 5026,848 held (−0%) | $323.62 | $16K | -28.1% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 4725,063 held (−0%) | $323.62 | $15K | -28.1% | — |
| Mar 4SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 4738,157 held (−0%) | $323.62 | $15K | -28.1% | — |
| Mar 4SEC | Pushkal GargEvp Chief R&D | Sell Plan | 4225,181 held (−0%) | $332.64 | $14K | -30.1% | — |
| Mar 4SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 3723,512 held (−0%) | $332.64 | $12K | -30.1% | — |
| Mar 4SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 3736,606 held (−0%) | $332.64 | $12K | -30.1% | — |
| Mar 2SEC | Pushkal GargEvp Chief R&D | Sell Plan | 2,25924,370 held (−8%) | $330.73 | $747K | -29.6% | — |
| Mar 2SEC | Pushkal GargEvp Chief R&D | Sell Plan | 1,15923,211 held (−5%) | $331.49 | $384K | -29.8% | — |
| Mar 2SEC | Pushkal GargEvp Chief R&D | Sell Plan | 94222,269 held (−4%) | $332.48 | $313K | -30.0% | — |
| Mar 2SEC | Pushkal GargEvp Chief R&D | Sell Plan | 14022,129 held (−1%) | $334.39 | $47K | -30.4% | — |
| Mar 2SEC | Pushkal GargEvp Chief R&D | Sell Plan | 12726,629 held (−0%) | $328.92 | $42K | -29.3% | — |
| Feb 17SEC | Yvonne GreenstreetCEO | Sell | 6,95885,662 held (−8%) | $310.08 | $2.2M | -25.0% | — |
| Feb 17SEC | Jeffrey V. PoultonCFO | Sell | 2,24259,802 held (−4%) | $310.08 | $695K | -25.0% | — |
| Feb 17SEC | Pushkal GargEvp Chief R&D | Sell | 2,24224,848 held (−8%) | $310.08 | $695K | -25.0% | — |
| Feb 17SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 2,04121,264 held (−9%) | $331.96 | $678K | -29.9% | — |
| Feb 17SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 1,95923,305 held (−8%) | $310.08 | $607K | -25.0% | — |
| Feb 17SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 1,95931,769 held (−6%) | $310.08 | $607K | -25.0% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 1,39580,264 held (−2%) | $365.56 | $510K | -36.3% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 1,25981,659 held (−2%) | $364.83 | $459K | -36.2% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 98084,307 held (−1%) | $360.22 | $353K | -35.4% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 77885,824 held (−1%) | $358.18 | $279K | -35.0% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 64422,151 held (−3%) | $370.00 | $238K | -37.1% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 62483,683 held (−1%) | $361.45 | $226K | -35.6% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 60786,602 held (−1%) | $357.17 | $217K | -34.9% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 58479,103 held (−1%) | $368.62 | $215K | -36.9% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 56222,795 held (−2%) | $368.76 | $207K | -36.9% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 53785,287 held (−1%) | $359.14 | $193K | -35.2% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 48521,666 held (−2%) | $371.24 | $180K | -37.3% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 46483,219 held (−1%) | $362.38 | $168K | -35.8% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 40558,004 held (−1%) | $365.56 | $148K | -36.3% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 36558,409 held (−1%) | $364.83 | $133K | -36.2% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 31679,948 held (−0%) | $366.41 | $116K | -36.5% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 30182,918 held (−0%) | $363.55 | $109K | -36.0% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 28021,386 held (−1%) | $372.93 | $104K | -37.6% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 28459,177 held (−0%) | $360.22 | $102K | -35.4% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 26179,687 held (−0%) | $367.40 | $96K | -36.7% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 26987,472 held (−0%) | $355.16 | $96K | -34.5% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 26387,209 held (−0%) | $356.09 | $94K | -34.7% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 25378,850 held (−0%) | $369.48 | $93K | -37.0% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 24787,741 held (−0%) | $353.95 | $87K | -34.3% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 22659,617 held (−0%) | $358.18 | $81K | -35.0% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 22023,846 held (−1%) | $365.56 | $80K | -36.3% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 22022,803 held (−1%) | $365.56 | $80K | -36.3% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 22030,020 held (−1%) | $365.56 | $80K | -36.3% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 19924,066 held (−1%) | $364.83 | $73K | -36.2% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 19923,023 held (−1%) | $364.83 | $73K | -36.2% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 19930,240 held (−1%) | $364.83 | $73K | -36.2% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 19723,357 held (−1%) | $367.52 | $72K | -36.7% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 18158,996 held (−0%) | $361.45 | $65K | -35.6% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 17659,843 held (−0%) | $357.17 | $63K | -34.9% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 17057,666 held (−0%) | $368.62 | $63K | -36.9% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 15659,461 held (−0%) | $359.14 | $56K | -35.2% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 15524,483 held (−1%) | $360.22 | $56K | -35.4% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 15523,440 held (−1%) | $360.22 | $56K | -35.4% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 15530,657 held (−1%) | $360.22 | $56K | -35.4% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 13558,861 held (−0%) | $362.38 | $49K | -35.8% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 12221,264 held (−1%) | $374.33 | $46K | -37.8% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 11878,505 held (−0%) | $375.65 | $44K | -38.1% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 12324,723 held (−0%) | $358.18 | $44K | -35.0% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 12323,680 held (−1%) | $358.18 | $44K | -35.0% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 12330,897 held (−0%) | $358.18 | $44K | -35.0% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 11878,732 held (−0%) | $370.87 | $44K | -37.3% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 9478,411 held (−0%) | $377.82 | $36K | -38.4% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 9824,385 held (−0%) | $361.45 | $35K | -35.6% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 9823,342 held (−0%) | $361.45 | $35K | -35.6% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 9830,559 held (−0%) | $361.45 | $35K | -35.6% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 9624,846 held (−0%) | $357.17 | $34K | -34.9% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 9623,803 held (−0%) | $357.17 | $34K | -34.9% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 9631,020 held (−0%) | $357.17 | $34K | -34.9% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 9223,663 held (−0%) | $368.62 | $34K | -36.9% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 9222,620 held (−0%) | $368.62 | $34K | -36.9% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 9229,837 held (−0%) | $368.62 | $34K | -36.9% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 9257,912 held (−0%) | $366.41 | $34K | -36.5% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 8878,623 held (−0%) | $374.44 | $33K | -37.9% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 8758,774 held (−0%) | $363.55 | $32K | -36.0% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 8524,638 held (−0%) | $359.14 | $31K | -35.2% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 8523,595 held (−0%) | $359.14 | $31K | -35.2% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 8530,812 held (−0%) | $359.14 | $31K | -35.2% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 7657,836 held (−0%) | $367.40 | $28K | -36.7% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 7860,095 held (−0%) | $355.16 | $28K | -34.5% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 7660,019 held (−0%) | $356.09 | $27K | -34.7% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 7357,593 held (−0%) | $369.48 | $27K | -37.0% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 7324,312 held (−0%) | $362.38 | $26K | -35.8% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 7323,269 held (−0%) | $362.38 | $26K | -35.8% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 7330,486 held (−0%) | $362.38 | $26K | -35.8% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 7260,173 held (−0%) | $353.95 | $25K | -34.3% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 5023,796 held (−0%) | $366.41 | $18K | -36.5% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 5022,753 held (−0%) | $366.41 | $18K | -36.5% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 5029,970 held (−0%) | $366.41 | $18K | -36.5% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 4724,265 held (−0%) | $363.55 | $17K | -36.0% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 4723,222 held (−0%) | $363.55 | $17K | -36.0% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 4730,439 held (−0%) | $363.55 | $17K | -36.0% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 4123,755 held (−0%) | $367.40 | $15K | -36.7% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 4122,712 held (−0%) | $367.40 | $15K | -36.7% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 4129,929 held (−0%) | $367.40 | $15K | -36.7% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 4224,983 held (−0%) | $355.16 | $15K | -34.5% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 4223,940 held (−0%) | $355.16 | $15K | -34.5% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 4231,157 held (−0%) | $355.16 | $15K | -34.5% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 4023,623 held (−0%) | $369.48 | $15K | -37.0% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 4022,580 held (−0%) | $369.48 | $15K | -37.0% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 4029,797 held (−0%) | $369.48 | $15K | -37.0% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 4124,942 held (−0%) | $356.09 | $15K | -34.7% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 4123,899 held (−0%) | $356.09 | $15K | -34.7% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 4131,116 held (−0%) | $356.09 | $15K | -34.7% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 3925,025 held (−0%) | $353.95 | $14K | -34.3% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 3923,982 held (−0%) | $353.95 | $14K | -34.3% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 3931,199 held (−0%) | $353.95 | $14K | -34.3% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 3657,557 held (−0%) | $370.87 | $13K | -37.3% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 3457,492 held (−0%) | $375.65 | $13K | -38.1% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 2757,465 held (−0%) | $377.82 | $10K | -38.4% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 2557,526 held (−0%) | $374.44 | $9K | -37.9% | — |
| Jan 14SEC | Yvonne GreenstreetCEO | Sell | 2178,711 held (−0%) | $372.46 | $8K | -37.5% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 1923,569 held (−0%) | $375.65 | $7K | -38.1% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 1922,526 held (−0%) | $375.65 | $7K | -38.1% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 1929,743 held (−0%) | $375.65 | $7K | -38.1% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 1923,604 held (−0%) | $370.87 | $7K | -37.3% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 1929,778 held (−0%) | $370.87 | $7K | -37.3% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 1822,562 held (−0%) | $370.87 | $7K | -37.3% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 1523,554 held (−0%) | $377.82 | $6K | -38.4% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 1522,511 held (−0%) | $377.82 | $6K | -38.4% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 1529,728 held (−0%) | $377.82 | $6K | -38.4% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 1423,588 held (−0%) | $374.44 | $5K | -37.9% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 1422,545 held (−0%) | $374.44 | $5K | -37.9% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 1429,762 held (−0%) | $374.44 | $5K | -37.9% | — |
| Jan 14SEC | Jeffrey V. PoultonCFO | Sell | 657,551 held (−0%) | $372.46 | $2K | -37.5% | — |
| Jan 14SEC | Pushkal GargEvp Chief R&D | Sell | 322,559 held (−0%) | $372.46 | $1K | -37.5% | — |
| Jan 14SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 223,602 held (−0%) | $372.46 | $745 | -37.5% | — |
| Jan 14SEC | Tolga TangulerEvp, Chief Commercial Officer | Sell | 229,776 held (−0%) | $372.46 | $745 | -37.5% | — |
| Nov 19SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 8,16825,224 held (−24%) | $449.00 | $3.7M | -48.2% | — |
| Nov 19SEC | Kevin Joseph FitzgeraldCso & Evp, Head Of Research | Sell Plan | 79423,211 held (−3%) | $458.41 | $364K | -49.2% | — |
Insiders at ALNYLAM PHARMACEUTICALS, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Yvonne GreenstreetCEO | — | $24.5M | Mar 6, 2026 | — |
| Kevin Joseph FitzgeraldCso & Evp, Head Of Research | — | $10.7M | Mar 6, 2026 | — |
| Pushkal GargEvp Chief R&D | — | $8.1M | Mar 6, 2026 | — |
| Jeffrey V. PoultonCFO | — | $5.0M | Mar 6, 2026 | — |
| Tolga TangulerEvp, Chief Commercial Officer | — | $3.1M | Mar 6, 2026 | — |
| Melissa MclaughlinChief Human Resources Officer | — | $1.3M | Apr 7, 2026 | — |
| David E I PyottDirector | — | $1.1M | Jun 3, 2026 | — |
| Bryan SupranGeneral Counsel | — | $399K | Oct 6, 2026 | — |
ALNY stock: common questions
Are ALNYLAM PHARMACEUTICALS, INC. insiders buying ALNY stock?
In the past 12 months, 0 insiders reported open-market purchases of ALNY worth $0.
Are ALNYLAM PHARMACEUTICALS, INC. insiders selling ALNY stock?
8 insiders reported sales worth $44.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ALNY's 52-week range?
Over the past year ALNY has traded between $205.48 and $491.22. It last closed at $232.68 on Oct 9, 2026.